{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T19:43:41Z","timestamp":1770234221959,"version":"3.49.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Parke-Davis Endowed Chair"},{"name":"Rutgers University, New Jersey, USA"},{"name":"Rutgers University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jconrel.2020.04.016","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T19:33:42Z","timestamp":1586892822000},"page":"71-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy"],"prefix":"10.1016","volume":"323","author":[{"given":"Firas","family":"Al-Zubaydi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipti","family":"Kakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shike","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Adler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Szekely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zichao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shicha","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Love","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0157-1895","authenticated-orcid":false,"given":"Patrick J.","family":"Sinko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.04.016_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.med.51.1.17","article-title":"Ductal carcinoma in situ of the breast","volume":"51","author":"Silverstein","year":"2000","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0010","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/jnci\/94.20.1546","article-title":"Detection of ductal carcinoma in situ in women undergoing screening mammography","volume":"94","author":"Ernster","year":"2002","journal-title":"JNCI"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0015","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajpath.2018.07.031","article-title":"Morphologic and molecular features of breast ductal carcinoma in situ","volume":"189","author":"Sanati","year":"2019","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0020","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0046-8177(97)90013-7","article-title":"Ductal carcinoma in situ of the breast: reproducibility of histological subtype analysis","volume":"28","author":"Scott","year":"1997","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1023\/A:1015816406078","article-title":"Ductal carcinoma in situ of the breast: a new phenotype classification system and its relation to prognosis","volume":"73","author":"W\u00e4rnberg","year":"2002","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0030","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.21069","article-title":"The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up","volume":"103","author":"Sanders","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-med-050715-104920","article-title":"Controversies in the treatment of ductal carcinoma in situ","volume":"68","author":"Barrio","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0040","first-page":"12","article-title":"Ductal carcinoma in situ of the breast","volume":"2012","author":"Lee","year":"2012","journal-title":"Int. J. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1245\/s10434-016-5501-z","article-title":"Are we overtreating ductal carcinoma in situ (DCIS)?","volume":"24","author":"Khan","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00192","article-title":"Paradigm shift toward reducing overtreatment of ductal carcinoma in situ of breast","author":"Sagara","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0055","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/bcr1397","article-title":"Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective","volume":"8","author":"Jones","year":"2006","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0060","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/(SICI)1098-2388(199609\/10)12:5<300::AID-SSU4>3.0.CO;2-H","article-title":"Management of ductal carcinoma in situ","volume":"12","author":"Talamonti","year":"1996","journal-title":"Semin. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1524-4741.1999.00130.x","article-title":"Optimal Management of Primary Breast Cancer","volume":"5","author":"Soran","year":"1999","journal-title":"Breast J."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0070","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1158\/0008-5472.CAN-05-4329","article-title":"Ductal access for prevention and therapy of mammary tumors","volume":"66","author":"Murata","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0075","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12609-010-0015-3","article-title":"Status of intraductal therapy for ductal carcinoma in situ","volume":"2","author":"Flanagan","year":"2010","journal-title":"Curr. Breast Cancer Rep."},{"issue":"Suppl 5","key":"10.1016\/j.jconrel.2020.04.016_bb0080","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1186\/1753-6561-3-S5-S29","article-title":"Local drug delivery to the breast: a phase 1 study of breast cytotoxic agent administration prior to mastectomy","volume":"3","author":"Love","year":"2009","journal-title":"BMC Proc."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002368","article-title":"Preclinical and clinical evaluation of intraductally administered agents in early breast cancer","volume":"3","author":"Stearns","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1158\/1940-6207.CAPR-12-0228","article-title":"A feasibility study of the intraductal administration of chemotherapy","volume":"6","author":"Love","year":"2013","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0095","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/jin2.51","article-title":"Evaluation of intraductal delivery of poly(ethylene glycol)-doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)-like lesions in rats","volume":"3","author":"Gu","year":"2018","journal-title":"J. Interdiscip. Nanomed."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0100","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s11095-012-0763-z","article-title":"Influence of molecular size on the retention of polymeric nanocarrier diagnostic agents in breast ducts","volume":"29","author":"Singh","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejps.2018.04.033","article-title":"The effect of size and polymer architecture of doxorubicin-poly(ethylene) glycol conjugate nanocarriers on breast duct retention, potency and toxicity","volume":"121","author":"Gu","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0110","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1080\/10717544.2018.1440665","article-title":"Multifunctional nanoemulsions for intraductal delivery as a new platform for local treatment of breast cancer","volume":"25","author":"Migotto","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0115","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1093\/carcin\/bgs248","article-title":"Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: implications for breast cancer chemoprevention in at-risk populations","volume":"33","author":"Chun","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0120","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2009-03-209965","article-title":"Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells","volume":"114","author":"Eberhard","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0125","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.exphem.2013.04.012","article-title":"Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity","volume":"41","author":"Sen","year":"2013","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0130","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/0008-5472.CAN-13-0474","article-title":"Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation","volume":"74","author":"Memin","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0135","first-page":"887","article-title":"Targeting the Wnt\/Beta-catenin pathway with the antifungal agent Ciclopirox Olamine in a murine myeloma model","volume":"25","author":"Kim","year":"2011","journal-title":"In Vivo"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0140","article-title":"Antileukemia effect of ciclopirox olamine is mediated by downregulation of intracellular ferritin and inhibition beta-catenin-c-Myc signaling pathway in glucocorticoid resistant T-ALL cell lines","volume":"11","author":"Wu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0145","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/ijc.25255","article-title":"The antitumor activity of the fungicide ciclopirox","volume":"127","author":"Zhou","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0150","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.23640","article-title":"Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies","volume":"89","author":"Minden","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0155","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/onc.2010.590","article-title":"The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway","volume":"30","author":"Luo","year":"2011","journal-title":"Oncogene"},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2020.04.016_bb0160","first-page":"5","article-title":"Zinc: health effects and research priorities for the 1990s","volume":"102","author":"Walsh","year":"1994","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0165","first-page":"817","article-title":"Applicability of zinc complex of L-Carnosine for medical use","volume":"65","author":"Matsukura","year":"2000","journal-title":"Biochem. Mosc."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0170","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1021\/cr900134a","article-title":"Application of metal coordination chemistry to explore and manipulate cell biology","volume":"109","author":"Haas","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0175","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1021\/bi00716a031","article-title":"Perturbation of liposomal and planar lipid bilayer membranes by bacitracin-cation complex","volume":"13","author":"MacDonald","year":"1974","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0180","series-title":"Neutrophil Accumulation, and TNF-\u03b1 Expression in Rats with Aspirin-Induced Gastric Mucosal Injury, Digestive Diseases and Sciences","first-page":"845","article-title":"Effects of polaprezinc on lipid peroxidation","volume":"46","author":"Naito","year":"2001"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0185","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/bmj.2.4844.1021","article-title":"Lente insulin (insulin zinc suspension): further studies","volume":"2","author":"Oakley","year":"1953","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0190","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejphar.2012.01.022","article-title":"Design, synthesis and characterization of zinc-3 hydroxy flavone, a novel zinc metallo complex for the treatment of experimental diabetes in rats","volume":"680","author":"Vijayaraghavan","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0195","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s13204-012-0188-3","article-title":"Nanosuspension for enhancement of oral bioavailability of felodipine","volume":"4","author":"Sahu","year":"2014","journal-title":"Appl. Nanosci."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0200","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ultsonch.2006.12.004","article-title":"Ultrasound-assisted crystallization (sonocrystallization)","volume":"14","author":"Luque de Castro","year":"2007","journal-title":"Ultrason. Sonochem."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0205","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/aic.690490905","article-title":"Chemical processing and micromixing in confined impinging jets","volume":"49","author":"Johnson","year":"2003","journal-title":"AICHE J."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0210","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1021\/mp400154a","article-title":"Determination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic Dialysis method","volume":"10","author":"Modi","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0215","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1155\/2014\/613619","article-title":"Experimental and mathematical studies on the drug release properties of aspirin loaded chitosan nanoparticles","volume":"2014","author":"Shi","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0220","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0021-9673(01)88470-3","article-title":"Micro-liquid chromatography method for the determination of ciclopiroxolamine after pre-column derivatization in topical formulations","volume":"553","author":"Belliardo","year":"1991","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0225","first-page":"779","article-title":"HPLC method for pharmacokinetic studies on ciclopirox olamine in rabbits after intravenous and intravaginal administrations","volume":"47","author":"Coppi","year":"1992","journal-title":"Farmaco (Societa chimica italiana : 1989)"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0230","doi-asserted-by":"crossref","first-page":"10140","DOI":"10.18632\/oncotarget.2471","article-title":"Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway","volume":"5","author":"Zhou","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0235","doi-asserted-by":"crossref","first-page":"e14705","DOI":"10.1200\/JCO.2019.37.15_suppl.e14705","article-title":"Pharmacokinetics of ciclopirox prodrug, a novel agent for the treatment of bladder cancer, in animals and humans","volume":"37","author":"Weir","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0240","doi-asserted-by":"crossref","first-page":"e14576","DOI":"10.1200\/JCO.2018.36.15_suppl.e14576","article-title":"Preclinical development of ciclopirox prodrug for the treatment of non-muscle invasive and muscle invasive bladder cancer","volume":"36","author":"Weir","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0245","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1158\/1538-7445.AM2018-5882","article-title":"Abstract 5882: bench-to-bedside translation of ciclopirox prodrug for the treatment of non-muscle invasive and muscle-invasive bladder cancer","volume":"78","author":"Weir","year":"2018","journal-title":"Cancer Res."},{"issue":"1_supplement","key":"10.1016\/j.jconrel.2020.04.016_bb0250","article-title":"Molecular mechanisms by which ciclopirox inhibits proliferation and induces apoptosis of tumor cells","volume":"25","author":"Shen","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0255","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/bcr2222","article-title":"Gene expression profiling of the tumor microenvironment during breast cancer progression","volume":"11","author":"Ma","year":"2009","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0260","first-page":"161","article-title":"Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast","volume":"151","author":"Simpson","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0265","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1365-2559.1998.00505.x","article-title":"Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins","volume":"33","author":"Quinn","year":"1998","journal-title":"Histopathology"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0270","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjc.6602932","article-title":"Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence","volume":"94","author":"Barnes","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0275","doi-asserted-by":"crossref","first-page":"60750","DOI":"10.18632\/oncotarget.18490","article-title":"Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice","volume":"8","author":"de Groot","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0280","doi-asserted-by":"crossref","first-page":"33306","DOI":"10.18632\/oncotarget.8949","article-title":"Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer","volume":"7","author":"Yoshida","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0285","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10549-012-2138-x","article-title":"Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors","volume":"135","author":"Chun","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"2010","key":"10.1016\/j.jconrel.2020.04.016_bb0290","first-page":"646","article-title":"Intraductal therapy for the prevention of breast cancer","volume":"11","author":"Jacobs","year":"2000","journal-title":"Curr. Opin. Investig. Drugs London, England"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0295","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1248\/cpb.38.3140","article-title":"Characterization of crystalline L-Carnosine Zn(II) complex (Z-103), a novel anti-gastric ulcer agent\u202f: tautomeric change of imidazole moiety upon complexation","volume":"38","author":"Matsukura","year":"1990","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0300","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2018\/1275486","article-title":"Antichronic gastric ulcer effect of zinc-Baicalin complex on the acetic acid-induced chronic gastric ulcer rat model","volume":"2018","author":"Yang","year":"2018","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0305","doi-asserted-by":"crossref","first-page":"24184","DOI":"10.1038\/srep24184","article-title":"Encapsulation of zinc-rifampicin complex into transferrin-conjugated silver quantum-dots improves its antimycobacterial activity and stability and facilitates drug delivery into macrophages","volume":"6","author":"Pati","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0310","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1211\/0022357044526","article-title":"An ocular drug delivery system containing zinc diethyldithiocarbamate and HP\u03b2CD inclusion complex - corneal permeability, anti-cataract effects and mechanism studies","volume":"56","author":"Wang","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0315","article-title":"Poly(lactic-co-glycolic acid) nanoparticles loaded with Callistemon citrinus phenolics exhibited anticancer properties against three breast cancer cell lines","volume":"12","author":"Ahmed","year":"2019","journal-title":"J. Food Qual."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0320","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.addr.2010.10.008","article-title":"PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect","volume":"63","author":"Acharya","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0325","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2009.02.018","article-title":"Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles","volume":"37","author":"Song","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0330","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijpharm.2015.01.002","article-title":"Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma","volume":"479","author":"Householder","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0335","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1080\/10717544.2016.1178825","article-title":"Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer","volume":"23","author":"Yuan","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0340","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.msec.2017.03.292","article-title":"Effects of curcumin-loaded PLGA nanoparticles on the RG2 rat glioma model","volume":"78","author":"Oruno\u011flu","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0345","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1208\/s12249-019-1327-x","article-title":"Preparation and evaluation of Irinotecan poly(lactic-co-glycolic acid) nanoparticles for enhanced anti-tumor therapy","volume":"20","author":"Yang","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2020.04.016_bb0350","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd1494","article-title":"Nanosuspensions in drug delivery","volume":"3","author":"Rabinow","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.04.016_bb0355","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1155\/2015\/216375","article-title":"Nanosuspension Technologies for Delivery of poorly soluble drugs","volume":"2015","author":"Yadollahi","year":"2015","journal-title":"J. Nanomater."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920302297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920302297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:47:13Z","timestamp":1759160833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920302297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":71,"alternative-id":["S0168365920302297"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.04.016","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast intraductal nanoformulations for treating ductal carcinoma in situ I: Exploring metal-ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}